Table 3 Immunohistochemical profiles of PRNRP, PRCC1, and PRCC2.

From: Recurrent KRAS mutations identified in papillary renal neoplasm with reverse polarity—a comparative study with papillary renal cell carcinoma

 

PRNRP (n, 30) % of cases (mean expression ± SD)

PRCC1 (n, 23) % of cases (mean expression ± SD)

PRCC2 (n, 26) % of cases (mean expression ± SD)

PRNRP vs PRCC1

p value

PRNRP vs PRCC2

p value

CK7

100 (100 ± 0)

96 (100 ± 0)

50 (75 ± 36)

0.893

<0.001

AMACR

63 (80 ± 33)

96 (100 ± 0)

100 (93 ± 21)

0.014

0.002

EMA

100 (100 ± 0)

96 (100 ± 0)

69 (82 ± 36)

0.893

0.008

Vimentin

17 (52 ± 46)

96 (100 ± 0)

85 (97 ± 13)

<0.001

<0.001

CD10

0

48 (51 ± 36)

73 (95 ± 21)

<0.001

<0.001

E-cadherin

77 (57 ± 37)

26 (70 ± 38)

12 (50 ± 46)

0.001

<0.001

Ki-67 (%)

1.30 ± 0.54

3.26 ± 1.66

5.65 ± 7.16

<0.001

0.005

  1. PRNRP papillary renal neoplasm with reverse polarity, PRCC1 papillary renal cell carcinoma type 1, PRCC2 papillary renal cell carcinoma type 2, AMACR alpha methylacyl co-A racemase, EMA epithelial membrane antigen, SD standard deviation
Back to article page